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Abstract
Double-walled carbon nanotubes (DWNTs) prepared by catalytic chemical vapour deposition
were functionalized in such a way that they were optimally designed as a nano-vector for the
delivery of small interfering RNA (siRNA), which is of great interest for biomedical research
and drug development. DWNTs were initially oxidized and coated with a polypeptide
(Poly(Lys:Phe)), which was then conjugated to thiol-modified siRNA using a
heterobifunctional cross-linker. The obtained oxDWNT–siRNA was characterized by Raman
spectroscopy inside and outside a biological environment (mammalian cells). Uptake of the
custom-designed nanotubes was not associated with detectable biochemical perturbations in
cultured cells, but transfection of cells with DWNTs loaded with siRNA targeting the green
fluorescent protein (GFP) gene, serving as a model system, as well as with therapeutic siRNA
targeting the survivin gene, led to a significant gene silencing effect, and in the latter case a
resulting apoptotic effect in cancer cells.
1. Introduction
In recent years, efforts have been dedicated to explore
the potential biological applications of carbon nanotubes
(CNTs), motivated by their size, shape and structures, as
well as their unique physical properties [1–3]. Double-
walled carbon nanotubes (DWNTs) bridge the gap between
single-walled carbon nanotubes (SWNTs) and multi-walled
carbon nanotubes (MWNTs). They are comparable to SWNTs
with respect to their small diameter, but their mechanical
stability is much higher than that of SWNTs. In addition,
the outer wall can be functionalized without changing the
mechanical and electronic properties of the inner tube [4].
These characteristics make them attractive for biomedical
applications, although there has also been concern about
potential harmful effects on living cells, which seem to
depend on a variety of physicochemical properties (e.g. length
and rigidity [5], aggregation behaviour [6], and surface
functionalization [7]) and should be monitored closely.
This study will tackle the challenges set for the field of
nanomedicine to create a more efficient and transparent path
for nano-product development, including standardization,
safety, and the ability to carry and deliver a therapeutic
payload [8].
Within the wide range of biomedical applications, CNTs
have recently been developed as gene therapy vectors as a
consequence of their ability to efficiently enter mammalian
cells. Gene therapy can be achieved through the insertion
of a gene (via plasmid DNA) into the host genome or
through molecules that silence the expression of a pathogenic
Figure 1. Schematic representation of uptake and release of siRNA
inside the cell for gene silencing. After internalization,
DWNT–siRNA complexes are trapped inside endosomes, which
maturate into lysosomes, whose acidic environment favours the
dissociation of siRNA from the DWNTs. The released siRNA is
then free to act as an effector molecule for specific cleavage of
target mRNA by RISC. The cleavage of the mRNA prevents the
production of a protein. Herein, siRNA is used to prevent expression
of survivin, an anti-apoptotic protein that is over-expressed in
cancer cells.
gene, such as silencing/small interfering RNA (siRNA).
siRNA consists of short double-stranded RNA segments
with typically 21–23 bases that are complementary to the
mRNA sequence of the protein whose transcription is to
be silenced/blocked [9]. Since RNA does not integrate into
the genome, it offers greater safety than plasmid molecules.
Furthermore, siRNA does not have to transfer through the
nuclear membrane for its activity, but exhibits its action in the
cytoplasm and therefore requires less sophisticated delivery
systems than plasmid DNA, promising faster development
and higher efficiencies [10]. The exact intracellular route for
siRNA delivered by a suitable carrier, such as DWNTs, is
shown in figure 1: after uptake, DWNT–siRNA complexes are
trapped inside endosomes, which subsequently mature into
acidic lysosomes, favouring the dissociation of the siRNA
from the polypeptide and its consequent release into the
cytoplasm. There, siRNA acts as an effector molecule for
specific cleavage of the target mRNA by the RNA-induced
silencing complex (RISC), leading to suppression of protein
synthesis.
In this study, mRNA of the survivin gene was employed
as a siRNA target. Survivin is part of the protein family
‘inhibitors of apoptosis’ (IAPs): it is highly expressed in a
number of human tumours and is also involved in tumour cell
resistance to anticancer drugs and ionizing radiation. Evasion
of apoptosis and the ability to proliferate uncontrollably
are two molecular traits found in all human cancers [11];
therefore, anti-apoptotic proteins involved in signalling
through specific apoptosis pathways provide attractive targets
for possible drug discovery and new anticancer interventions;
particularly those based on gene silencing. In this case,
elimination of the survivin pathway leads to the lowering of
the anti-apoptotic threshold in cancer cells and thus directly
causes apoptosis [12], i.e. the suicide of unhealthy, cancerous
cells.
Carbon nanotubes have been successfully employed as
a delivery system for a variety of genes and other nucleic
acids. In one of the pioneer studies, Kam et al reported potent
gene silencing by means of siRNA delivery using CNTs.
They observed a silencing effect of over 2-fold using SWNTs
in comparison with Lipofectamine R©, a common transfection
agent used in molecular biology [13]. A follow-up study
achieved silencing of a therapeutic target, i.e. the expression
of a HIV-specific cell surface co-receptor to block HIV virus
entry [14]. In both cases, the applied functionalization scheme
was based on cleavable disulfide bonds, which we have
adapted for the study presented here. One of the first in
vivo studies using siRNA delivered by carbon nanotubes as
a therapeutic agent has been carried out by Podesta et al, who
used amino-functionalized MWNTs to deliver a proprietary,
toxic siRNA sequence to a human lung tumour xenograph
model after intratumoral application, which resulted in tumour
growth inhibition and prolonged survival of tumour-bearing
animals [15]. Overall, this demonstrates that carbon nanotubes
present a versatile and promising method for siRNA delivery
that can potentially be applied for the treatment of a wide
range of illnesses. The aim of our study is to investigate the
feasibility of using double wall carbon nanotubes (DWNTs)
as a new delivery vector for ‘anticancer’ siRNA targeting the
gene survivin, a major factor in contributing to the resistance
of cancer cells to apoptosis.
2. Experimental details
2.1. Synthesis of DWNTs
DWNTs were produced by catalytic chemical vapour
deposition (CCVD) through decomposition of CH4 over
Mg1−xCoxO solid solution containing small quantities of
molybdenum in the reactor [4]. For purification purposes
and to achieve solubility in aqueous media and physiological
environments, DWNTs were subjected to a mixture of nitric
and sulfuric acid as described in previous studies [16, 17]
with subsequent removal of agglomerates and bundles by
ultracentrifugation. After oxidation, nanotubes were sterilized
by autoclaving at 121 ◦C for 1 h and maintained under
sterile conditions for the duration of the experiment. The
final product consists of single or small bundles of shorter
nanotubes and will henceforth be called ‘oxDWNTs’.
2.2. Wrapping of oxidized CNTs
oxDWNTs at a concentration of 100 µg ml−1 were mixed
with 50 µg ml−1 of Poly(Lys:Phe) in phosphate buffer
(20 mM, pH 7.5) by continuous stirring for 2 h at room
temperature (∼ 21 ◦C). To remove unbound polypeptide
molecules, the solution was filtered using 100 kDa filter
devices (Amicon Ultra-4 centrifugal filter devices from
Millipore). Next, Poly(Lys:Phe)-wrapped nanotubes were
resuspended in DNase/RNase-free water (Sigma Aldrich,
Poole, UK) to a final DWNT concentration of 100 µg ml−1.
Figure 2. Attachment of thiol-modified siRNA to Poly(Lys:Phe)-wrapped oxDWNTs using the heterobifunctional cross-linker
‘Sulfo-LC-SPDP’.
2.3. Conjugation with siRNA
oxDWNTs were wrapped with Poly(Lys:Phe) and subse-
quently mixed with non-specific RNA for Raman experiments
(henceforth called ‘oxDWNT–siRNA’) or siRNA targeting the
GFP gene (Silencer R© GFP (eGFP) siRNA and negative con-
trol, purchased from Ambion R© Life Technologies, UK) for
proof-of-principle silencing experiments (henceforth called
‘oxDWNT–siRNAGFP’), which allowed for siRNA binding
by electrostatic interactions. Excess siRNA was removed
by filtration with 100 kDa filter devices (Amicon Ultra-4
centrifugal filter devices from Millipore) and the obtained
oxDWNT–siRNA resuspended in DNase/RNase-free water
(Sigma Aldrich, Poole, UK) at a final DWNT concentration
of 100 µg ml−1.
For experiments with therapeutic siRNA targeting
the gene survivin (siRNAsurvivin) we decided to pursue
another approach, which allows for intracellular siRNA
detachment in a more controlled way, i.e. by cleavage
of the disulfide bond by thiol-reducing enzymes aided
by the acidic pH in lysosomes (based on a previous
study by Kam et al [13]). Here, oxDWNTs were first
functionalized with the cationic polypeptide Poly(Lys:Phe)
and then conjugated with a heterobifunctional cross-
linker containing a disulfide bond (succinimidyl 6-[3-(2-
pyridyldithio)-propionamido] hexanoate, henceforth called
‘Sulfo-LC-SPDP’, from Pierce/Thermo Fisher Scientific,
UK), which is designed for amine-to-sulfhydryl conjugation
and readily reacts with thiol-modified siRNAsurvivin (figure 2).
Twentyfive microlitres of Sulfo-LC-SPDP (20 mM) were
combined with prepared oxDWNT-Poly(Lys:Phe) diluted
1:1 in PBS (20 mM, pH 7.5) and incubated for 1 h
at room temperature (∼ 21 ◦C) under continuous stirring.
Excess cross-linker was removed by filtration using 100 kDa
filter devices (Amicon Ultra-4 centrifugal filter device from
Millipore). Next, thiol-modified siRNA with the sequence
5′-Th CCACUGAGAACGAGCCAGAUU (J-003459-11) to
target survivin was mixed with oxDWNT-Poly(Lys:Phe)
cross-linker and allowed to react for 1 h at room temperature
under continuous stirring. The solutions were again filtered
using a 100 kDa filter device (Amicon Ultra-4 centrifugal
filter devices from Millipore) to remove excess siRNA and
then resuspended in DNase/RNase-free water (Sigma Aldrich,
Poole, UK) at a final DWNT concentration of 100 µg ml−1 to
obtain oxDWNT–siRNAsurvivin.
2.4. Cell culture
Human prostate cancer cells PC3 (ECACC, Porton Down,
Salisbury, UK) were cultured in RPMI-1640 medium
supplemented with 10% (v/v) foetal bovine serum (FBS),
2 mM GlutamaxTM and 1% (v/v) penicillin–streptomycin (all
obtained from Invitrogen, Paisley, UK). Cells were cultured
in 35 mm sterile petri dishes (Nunc, Thermo Scientific)
containing glass coverslips.
2.5. Raman mapping of single cells
In order to investigate cellular uptake and toxicity,
human prostate cancer cells PC3 were incubated with
oxDWNT–RNA (30 µg ml−1 diluted in Opti-MEM serum-
free cell culture medium) for up to 3 h. Assessment of DWNT
uptake was performed at different time points ranging from
0.5 to 24 h. After 3 h of incubation with, the cells were washed
twice with ice-cold, sterile PBS, to remove oxDWNT–RNA
from the medium and fresh medium containing serum and
antibiotics was added. At the end of each time point (0, 0.5, 3,
6, 9, 12, 18 and 24 h) the medium was removed and the cells
washed several times with PBS. Cells were subsequently fixed
with 4% paraformaldehyde solution (Sigma Aldrich, Poole,
UK) to prevent morphological and chemical changes during
data acquisition. Finally, the samples were again washed with
PBS and slides mounted and hermetically sealed using nail
lacquer. Raman mapping was performed using a Renishaw
InVia Raman microscope, Elaser = 1.59 eV (785 nm excitation
wavelength). The radial breathing modes (RBMs) that are
characteristic for carbon nanotubes were used to map the
intensity of oxDWNT–RNA in cells and to extrapolate the
nanotube diameters present in the mixture using the equation
ωRBM = 248/dt, with ωRBM being the RBM frequency in
cm−1 and dt the tube diameter in nm [18].
2.6. Raman spectroscopy of whole cell lysates
While the distribution of DWNTs inside cells was monitored
by Raman spectroscopy of whole cells, biochemical changes
of cell constituents within this time frame was monitored
by Raman spectroscopy of whole cell lysates. For that,
PC3 cells were grown in medium as described above
and cultured in 25 cm2 tissue culture flasks until 80%
confluence was reached. At this point, cells were incubated
with oxDWNT–RNA (30 µg ml−1 final DWNT concentration
after dilution in serum-free Opti-MEM medium) for various
times ranging from 0.5 to 24 h. After 3 h incubation,
the medium containing oxDWNT–RNA was replaced with
fresh medium containing serum and antibiotics after two
washing cycles with PBS. At each time point, the medium
was removed from the cells, followed by several washes
with PBS. The cells were subsequently trypsinized, washed
with ice-cold PBS, and ruptured via hypotonic shock using
a lysis buffer (Tris buffer containing 50 mM Tris HCl
and 150 mM NaCl at pH 7.5 and additionally 1% NP-40,
0.2% SDS, 1 mM phenylmethanesulfonyl fluoride (PMSF),
10 µg ml−1 aprotinin, 10 µg ml−1 leupeptin, 1 mM sodium
orthovanadate (Na3VO4) as cellular protease inhibitors). After
lysis, suspensions were spun down for 10 min at 500g
and 4 ◦C (Eppendorf 5415R, Hamburg, Germany) to remove
nuclei and unbroken cells, and supernatants were used to
evaluate the DWNT content. For Raman measurements,
a droplet of cell lysate (4 µl) was allowed to dry on
a glass slide. Spectra of samples were recorded using a
NT-MDT NTEGRA Spectra Probe NanoLaboratory inverted
configuration microscope (Elaser = 2.64 eV or 473 nm).
2.7. GFP knockdown in HeLa and PC3 cells
Stable cell lines expressing green fluorescent protein
(GFP) were produced via transfection with pAcGFP-N1
plasmid (Clonetech, Saint-Germain-en-Laye, France) using
Lipofectamine R© according to instructions in the manual.
GFP-expressing cells were selected using 600 µg ml−1 of
Geneticin R© (Gibco/Invitrogen, Parsley, UK). After 4 weeks
of selection cells were sorted by fluorescence-activated cell
sorting (FACS), whereby 80–90% GFP-expressing cells were
obtained. These cells were allowed to recover for 8 weeks and
re-sorted once more for further purification. The expression
of GFP allows for visualization by confocal microscopy
(excitation at 488 nm and 400 mW power emission using an
argon laser; detection using a 535 nm ± 15 nm band pass
filter).
For oxDWNT–siRNAGFP transfection, the previously
prepared complexes were diluted 1:2 in Opti-MEM R© medium
(Invitrogen, Paisley, UK). For comparison with a commer-
cially available transfection agent serving as the positive
control, Lipofectamine R© RNAiMAX, siRNAGFP complexes
were prepared according to the manufacturer’s instructions (1
or 6 µl Lipofectamine R© RNAiMAX, for use in 24-well or
35 mm plates, respectively, were combined with 0.2–1 µM
siRNAGFP and added to each corresponding well). After
4 h the medium was replaced with fresh complete medium
containing serum. The cells were then incubated for further
48 h at 37 ◦C in a CO2 incubator.
To evaluate gene knockdown, cells were fixed with 4%
paraformaldehyde (Sigma Aldrich, Poole, UK) in PBS for 1 h
at room temperature, followed by washing with sterile PBS
and treatment with 0.1% Triton X100 (Sigma Aldrich, Poole,
UK) in PBS for 15 min to permeabilize cell membranes. Cells
were then washed three-times with PBS and TO-PRO R©-3
iodide (Molecular Probes R©, 0.1 µM in PBS), a monomeric
cyanine nucleic acid stain, was utilized to stain the nuclei in
all samples. Images were captured at 63×magnification using
a Zeiss LSM 510 inverted confocal microscope and analysed
using LSM 510 META software. To determine the percentage
of GFP knockdown after siRNAGFP delivery, cells were
counted in five different fields. GFP-expressing cells appear
green (GFP, emission 505 nm) with the nucleus coloured in
blue (TO-PRO R©-3, emission 661 nm), while non-expressing
cells only exhibit nuclear staining.
2.8. Survivin knockdown in PC3 cells
To achieve knockdown of the survivin gene in PC3 cells,
cells were incubated with oxDWNT–siRNAsurvivin for 4 h
and maintained for 3–7 days to allow for gene silencing to
occur. PC3 cells were initially seeded 24 h prior to transfection
to obtain 50% confluency at the time of transfection in
35 mm sterile petri dishes. oxDWNT–siRNAsurvivin prepared
as described in the previous section was diluted 1:2 in
Opti-MEM R© medium (Invitrogen, Paisley, UK). Again, a
commercial transfection agent, DharmaFECT R©, was used
to serve as the positive control. DharmaFECT–siRNAsurvivin
complexes were prepared according to the manufacturer’s
instructions: 3 µl DharmaFECT R© reagent was combined with
400 µl of serum-free culture medium and incubated for 5 min
at room temperature. Next, siRNAsurvivin was diluted in 400µl
of media to a final concentration of 0.8 µM per 35 mm
plate. The solutions were then combined and incubated at
room temperature for a further 20 min, before being added to
the corresponding wells. After 4 h the medium was replaced
with fresh complete medium (containing 10% serum) for both
samples. The cells were then incubated for a further 72 h at
37 ◦C in a CO2 atmosphere in order to achieve a silencing
effect. After 72 h incubation cells were trypsinized and split
for further incubation up to 120 h. Cells were then stained with
Trypan Blue and counted using a haemocytometer.
The level of apoptosis induced by silencing of the
survivin gene was evaluated by means of the Annexin V Biotin
Apoptosis Detection Kit (CalBioChem R©) and subsequent
analysis by flow cytometry, which permits determination of
the percentage of viable cells, cells in early apoptotic stage,
late apoptotic stage, and dead cells. Untreated cells, as well as
cells treated with transfection agent but without siRNAsurvivin
served as negative controls. For these experiments, cells
floating in the medium, as well as cells growing in a
monolayer were recovered and combined for an apoptosis
assay using the previously described kit. Combined cells
were spun down and resuspended in 500µl of medium. Next,
10 µl medium binding reagent and 2 µl Annexin V-FITC
were added and the mixture incubated for 30 min at room
temperature in the dark. Following incubation, cells were
spun down and resuspended in 500 µl of a cold one-time
binding buffer. After that, 10 µl propidium iodide was added
Figure 3. Raman spectrum of DWNTs (A) and mapping of oxDWNT–RNA inside a cell (B). (A) DWNT Raman spectrum featuring the
characteristic Raman bands: RBM (150, 200, 230 and 260 cm−1); D-band (1350 cm−1); G-band (1590 cm−1) and 2D-band (2600 cm−1).
(B) Raman mapping of RBM mode (160 cm−1) in a single cell (inset). A high intensity is observed in the cell, but not in the surrounding
area.
and samples were placed on ice and away from light, before
analysis by flow cytometry. Note that this assay can only
be performed on live cells and it is unsuitable for fixed
material. Measurements were obtained using the Beckman
Coulter Epics XL flow cytometer analyser. Data analysis was
performed utilizing FlowJo software.
3. Results
oxDWNTs were found to consist of single or small bundles
of shorter nanotubes (200–2000 nm length, 296 nm ±
123 nm on average as determined by AFM and phase-analysis
light scattering (PALS) [17]). TEM analysis (figure S1 in
the supporting information available at stacks.iop.org/Nano/
23/365102/mmedia) confirmed the Poly(Lys:Phe) coating
of Poly(Lys:Phe)-wrapped oxDWNTs. Analysis by Raman
spectroscopy revealed distinct peaks characteristic of DWNTs
(figure 3a): the radial breathing modes (RBMs) at 150, 200,
230 and 260 cm−1 (correlating with diameters of 0.9, 1.1,
1.2 and 1.58 nm [18]), as well as the D-band (1350 cm−1),
G-band (1590 cm−1), and the 2D-band (2600 cm−1), which
can be clearly observed in the spectrum. Figure 3(b) shows
a Raman map of the RBM in a mammalian cell, which
has previously been exposed to oxDWNT–RNA. A strong,
locally confined Raman signal was detected within the
whole cell, confirming successful DWNT uptake and possible
localization within endosomes, as also reported in previous
work by our group, which has looked at the intracellular
distribution of functionalized DWNTs in greater detail [19,
20].
An important factor for the design of DWNTs as a
nano-vector is that they do not significantly modify the cell
environment, so that perturbations due to the payload can be
detected. Raman spectroscopy can serve as a powerful tool to
assay biochemical changes in cells [19, 21]. Indeed, Raman
spectra of oxDWNT–RNA inside cells (obtained by analysing
whole cell lysates) exhibited several peaks in addition to
those observed for DWNTs alone, of which some can be
contributed to cell constituents. Figure 4 plots three of those
peaks and their variation over time (24 h time frame): DNA
backbone stretching at 1090 cm−1 [22], the CH bending
mode of proteins and lipids at 1450 cm−1 [23], and amide
I α-helix vibrations of proteins at 1660 cm−1 [24]. The DNA
backbone stretching (O–P–O) Raman peak has been described
as suitable for monitoring the process of cell death due to
its integral association with DNA disintegration [22]. When
a comparison was made between cells exposed to DWNTs
and unexposed controls, it was found that identical forms and
patterns were maintained.
Next, we investigated the ability of oxDWNTs to bind
and deliver siRNA into cells. siRNA has a vast potential as
a therapeutic agent for various disorders, but cannot cross
the cell membrane on its own due to its negative charge,
and is prone to degradation by nucleases inside the cell.
In this case, we used oxDWNTs to deliver two types of
siRNA: first, siRNA to silence the GFP gene as a proof of
principle (siRNAGFP), and secondly, siRNA to silence the
gene survivin, which has therapeutic value for cancer therapy
(siRNAsurvivin).
Figure 5 shows fluorescent micrographs of GFP-
expressing cells treated with different concentrations
of siRNAGFP. Under the employed conditions, both
lipofectamine R© and oxDWNTs showed negligible toxicity.
Control cells and cells treated with non-specific siRNA
(siRNAneg) displayed around 80% cells expressing GFP.
The treatment with 50 nM of bound siRNAGFP using
lipofectamine R© as delivery agent produced a pronounced
effect in GFP expression in both cells lines, which decreased
to a level of about 20% in Hela cells and 45% in PC3
cells. Treatment with 100 nM bound siRNAGFP delivered
by lipofectamine R© decreased GFP expression to a level of
about 8% and 21%, respectively. The knockdown effect using
oxDWNT–siRNAGFP was lower than for the positive control
lipofectamine, but nevertheless a significant decrease in GFP
expression to a level of about 50% was observed after only
48 h.
We next investigated the delivery of therapeutic siRNA
targeting the gene survivin by the developed oxDWNT
vectors. Figure 6 reveals the effect of siRNAsurvivin delivery
Figure 4. Time-dependent analysis of cell constituents by Raman spectroscopy after exposure to oxDWNT–RNA: DNA, protein/lipids and
protein structure (amide I α-helix). Cell constituents were not disturbed through incubation with oxDWNT–siRNA in comparison with
control cells.
Figure 5. Percentage of cells expressing GFP in HeLa and PC3 cells treated with siRNAGFP. GFP stable cell lines were produced via a
protocol of 4-week selection to obtain 80–90% GFP-expressing cells, using fluorescence-activated cell sorting (FACS). GFP knockdown
was achieved using either oxDWNTs or a common transfection reagent (Lipofectamine R©) serving as the positive control, and was
determined by confocal microscopy by counting GFP-expressing cells (green cytoplasm plus blue nucleus) against non-expressing cells
(blue nucleus only). siRNAGFP delivery by lipofectamine produced around 89% knockdown of GFP in Hela cells and 69% in PC3 cells for
the 100 nM sample, while oxDWNTs–siRNAGFP at 100 nM siRNAGFP concentration induced about 40% knockdown in Hela cells and 29%
knockdown in PC3 cells in comparison with the negative control. Results are presented as mean ± SEM (n = 5).
using oxDWNTs, again in comparison with a common
transfection reagent (DharmaFECT R©) and untreated cells
(PC3 cells only and cells treated with DharmaFECT R© only).
The results showed similar levels of apoptosis for cells treated
with siRNAsurvivin delivered by oxDWNTs (35.89%) and by
DharmaFECT R© transfection agent (44.92%), which are both
significantly higher than the two controls; cells only (5.22%)
and cells treated with DharmaFECT R© only (18.64%).
4. Discussion
The selective and robust effect of RNA interference on gene
expression, mediated by siRNA, makes it not only a valuable
research tool, but also a promising therapeutic platform for
the treatment of viral infections, dominant disorders, cancer,
and neurological disorders [25]. In this paper, we focused
on the delivery of siRNA targeting the gene survivin as a
potential treatment for a range of cancers, as the survivin
Figure 6. Flow cytometry analysis of apoptosis in cells treated with
siRNAsurvivin, showing percentages of cells at different apoptotic
stages for each treatment. PC3 cells only and PC3 cells treated with
DharmaFECT R© only served as the negative controls and
siRNAsurvivin transfected using the commercial transfection agent
DharmaFECT R©(DharmaFECT–siRNA) as the positive control. A
similar apoptotic effect was obtained for oxDWNT–siRNAsurvivin
than for the positive control DharmaFECT–siRNAsurvivin.
protein regulates apoptosis and controls cell proliferation and
is expressed highly in most human tumours and foetal tissue,
but is completely absent in terminally differentiated cells.
The successful delivery of siRNA to target specific genes
in mammalian model organisms has been achieved using
a variety of methods, including liposomes, cationic lipids,
polymers and nanoparticles. However, systemic toxicity
remains a great concern with most of these delivery options.
Thus, there is an ever-growing need to enhance the available
tools that can lead to effective and safe gene delivery. The
functionalized oxDWNTs developed in this work present
an alternative with reasonable biocompatibility, which can
simultaneously serve as an imaging agent due to their unique
Raman signature within biological environments (figure 3).
DWNTs have an important advantage over SWNTs, for
which any structural damage disrupts their mapping and
progression over time. Furthermore, as we have shown in
previous studies, they are released from the cells within
24 h after having fulfilled their task and do not accumulate
within cells [20]. In this study we investigated whether
oxDWNT–RNA causes any changes in the cell biochemistry
within this time frame, which they did not (figure 4). This is
in good agreement with a previous study of our group, which
has shown that oxDWNT–RNA did not cause phosphorylation
of mitogen-activate protein kinases (MAPKs), which are
markers for induced cellular stress [19]. In addition, we
have also previously investigated the effect of oxDWNTs on
cell viability after 96 h incubation by a MTT cytotoxicity
assay and found no dose-dependent toxicity, although an
overall drop of cell viability of about 5–15% was observed,
possibly due to inhibition of cell proliferation or decreased
cell adhesion [17]. Overall, this indicates that oxDWNT–RNA
does not have a deleterious effect on cells during their passage,
although long-term effects remain to be investigated.
In terms of therapeutic efficacy, the achieved silencing
effect (‘gene knockdown’) was either lower than commercial
transfection agents (GFP–siRNA/lipofectamine R©, figure 5)
or at a comparable level (survivin siRNA/DharmaFECT R©,
figure 6). Considering that most commercially available
in vitro transfection agents are unsuitable for therapeutic
applications due to their systemic toxicity, this indicates that
DWNTs may be successfully employed to deliver therapeutic
moieties, such as siRNA, to cells for the treatment of
cancerous disorders, as demonstrated in this study. Future
work will need to be done to study the in vivo performance
of our system, which will show whether oxDWNTs do
have an advantage over cationic lipid-based transfection
agents (e.g. lipofectamine R© and DharmaFECT R©) due to
improved biocompatibility, and will allow for a comparison
of the in vivo performance of oxDWNTs with other carbon
nanotube-based delivery systems in the literature.
5. Conclusions
In summary, we show that short oxDWNTs produced by
CCVD and subsequent acid treatment and functionalization
are suitable for the delivery of therapeutic moieties and do not
exhibit the toxic effects that have been attributed to longer
CNTs [5]. Their unique Raman spectral features, such as
the RBM, allow for their detection inside cells by Raman
spectroscopy, while simultaneously enabling the detection of
changes in cell biochemistry following oxDWNT uptake. It
is demonstrated that during a period of 24 h RNA-wrapped
oxDWNTs did not cause detectable changes in the cells’
DNA, protein or lipid content. Our final goal, however, was
to use oxDWNTs as a nano-vector for therapeutic payloads to
achieve a clinically relevant effect. After loading oxDWNTs
with siRNA to block the expression of the anti-apoptotic
protein survivin, which is over-expressed in most human
tumours, we successfully demonstrated apoptosis of cells
after transfection with oxDWNT–siRNAsurvivin complexes to
a similar level as obtained with siRNAsurvivin delivered by a
standard siRNA transfection agent. It should be noted that
although transfection agents are able to efficiently transport
siRNA into cultured cells, they are unsuitable for therapeutic
applications due to their systemic toxicity. The study thereby
advances the goal of developing nano-vectors for safe and
efficient delivery of therapeutic payloads.
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